Betaferon, BAY86-5046 — Competitive Intelligence Brief

Betaferon, BAY86-5046 (Betaferon, BAY86-5046) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulator. Area: Immunology.

phase 2 Immunomodulator Interferon-gamma Immunology Small molecule

Target snapshot

Betaferon, BAY86-5046 (Betaferon, BAY86-5046) — Bayer. Betaferon is an immunomodulatory drug that works by inhibiting the production of interferon-gamma, a cytokine involved in the immune response.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Betaferon, BAY86-5046 TARGET	Betaferon, BAY86-5046	Bayer	phase 2	Immunomodulator	Interferon-gamma
Gamma Interferon 1b	Gamma Interferon 1b	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	marketed	Cytokine; Interferon	Interferon-gamma receptor (IFNGR)
Interferon-gamma, Recombinant	Interferon-gamma, Recombinant	Radboud University Medical Center	phase 3	Cytokine	Interferon-gamma receptor (IFNGR)
Hydroxychloroquine Sulfate Regular dose	Hydroxychloroquine Sulfate Regular dose	Government of Punjab, Specialized Healthcare and Medical Education Department	marketed	Quinoline antimalarial and immunomodulator	Lysosomal pH regulation; toll-like receptors (indirect)
PF-06863135 + lenalidomide	pf-06863135-lenalidomide	Pfizer	marketed	small molecule + immunomodulatory drug	unknown
Ixazomib plus low-dose lenalidomide	Ixazomib plus low-dose lenalidomide	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Proteasome inhibitor and immunomodulatory agent	Proteasome and cereblon
FTY720	FTY720	Novartis Pharmaceuticals	marketed	Sphingosine-1-phosphate receptor modulator; Immunomodulator	Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulator class)

1. Actavis Mid-Atlantic LLC · 1 drug in this class
2. Active Biotech AB · 1 drug in this class
3. Air Force Military Medical University, China · 1 drug in this class
4. Astellas Pharma Inc · 1 drug in this class
5. Bayer · 1 drug in this class
6. Beijing Children's Hospital · 1 drug in this class
7. Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
8. Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri · 1 drug in this class
9. Chang Gung Memorial Hospital · 1 drug in this class
10. ALK-Abelló A/S · 1 drug in this class